Nicholas Maestas
Net worth: 903 $ as of 30/05/2026
Net worth: 903 $ as of 30/05/2026
Nicholas Maestas worked at Immune Design Corp.
from 2014 to 2019, serving as Senior Director-Corporate Development & Operations in 2019.
From 2019 to 2021, worked at Alector, Inc. as Head-Financial Planning & Analysis.
From 2025 to 2026, worked at Tempest Therapeutics, Inc. as Chief Financial Officer, Secretary & Head-Strategy.
Education includes undergraduate studies at the University of California, Berkeley and an MBA from The Wharton School of the University of Pennsylvania.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 30/03/2026 | 590 ( 0% ) | 903 $ | 30/05/2026 |
| Companies | Position | End |
|---|---|---|
| TEMPEST THERAPEUTICS, INC. | Director of Finance/CFO | 04/06/2026 |
| ALECTOR, INC. | Corporate Officer/Principal | 30/06/2021 |
| IMMUNE DESIGN CORP | Corporate Officer/Principal | 30/06/2019 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune Design Corp.
Immune Design Corp. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical and clinical-stage immunotherapy company | Health Technology |
Alector, Inc.
Alector, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for Alzheimer’s disease and other neurodegenerative disorders | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology pharmaceuticals | Health Technology |
Select your edition
All financial news and data tailored to specific country editions